PAVmed (NASDAQ:PAVM) Chairman Lishan Aklog bought 2,300 shares of PAVmed stock in a transaction on Monday, November 21st. The shares were purchased at an average price of $10.02 per share, for a total transaction of $23,046.00. Following the acquisition, the chairman now directly owns 22,500 shares in the company, valued at approximately $225,450. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Lishan Aklog also recently made the following trade(s):

  • On Friday, September 16th, Lishan Aklog bought 1,300 shares of PAVmed stock. The shares were purchased at an average price of $14.05 per share, for a total transaction of $18,265.00.
  • On Wednesday, September 14th, Lishan Aklog bought 1,500 shares of PAVmed stock. The shares were purchased at an average price of $13.40 per share, for a total transaction of $20,100.00.
  • On Friday, August 26th, Lishan Aklog bought 400 shares of PAVmed stock. The shares were purchased at an average price of $14.30 per share, for a total transaction of $5,720.00.
  • On Wednesday, August 24th, Lishan Aklog bought 1,500 shares of PAVmed stock. The shares were purchased at an average price of $14.22 per share, for a total transaction of $21,330.00.

PAVmed (NASDAQ:PAVM) traded down 0.0011% on Wednesday, hitting $9.1999. The company’s stock had a trading volume of 1,110 shares. The firm’s market cap is $122.45 million. The firm has a 50 day moving average of $11.51 and a 200 day moving average of $12.91. PAVmed has a 12 month low of $8.85 and a 12 month high of $15.24.

WARNING: This article was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another site, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this article can be accessed at https://www.thecerbatgem.com/2016/11/23/pavmed-pavm-chairman-lishan-aklog-acquires-2300-shares.html.

5 Day Chart for NASDAQ:PAVM

Receive News & Stock Ratings for PAVmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed and related stocks with our FREE daily email newsletter.